415: Mistrust in science and a juicy gene-editing lawsuit

The erosion of public trust in science stems from complex emotional responses rather than simple misinformation, as scientific knowledge frequently collides with fear and frustration. While childhood vaccination rates decline, the pharmaceutical industry’s shift toward marketing GLP-1 products as lifestyle "glow-up" tools risks further commodifying medicine and alienating patients who view obesity as a serious disease. Meanwhile, Unicure’s gene therapy for Huntington’s disease shows waning efficacy at four years, complicating the path to regulatory approval. Simultaneously, legal disputes between Beam Therapeutics and Chinese competitors highlight growing industry anxieties over intellectual property theft and global competition. Addressing these challenges requires moving beyond mere fact-checking to understanding the lived experiences of those skeptical of medical institutions, especially as skepticism becomes an official perspective within federal health policy.